Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
| Revenue (TTM) | $46.17M |
| Gross Profit (TTM) | $36.59M |
| EBITDA | $-5.97M |
| Operating Margin | -4.37% |
| Return on Equity | -988.00% |
| Return on Assets | -17.40% |
| Revenue/Share (TTM) | $3.92 |
| Book Value | $0.51 |
| Price-to-Book | 2.74 |
| Price-to-Sales (TTM) | 0.37 |
| EV/Revenue | 0.418 |
| EV/EBITDA | -0.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 32.90% |
| Shares Outstanding | $12.80M |
| Float | $10.50M |
| % Insiders | 11.99% |
| % Institutions | 20.72% |
Volatility is currently contracting
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive sun protection Actinic Keratosis affects an estimated 58 million Americans and, if left untreated, can develop into squamous cell carcinoma1 Woburn, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the return of the Hats On Campaign for its second consecutive year.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BFRI and any ticker you trade — then tracks every position and per-strategy win rate.
